Abstract
AbstractThis review discusses the role of basal insulin therapy in the treatment of patients with type 1 and type 2 diabetes in the light of the availability of a new long‐acting analogue, insulin glargine. The critical role of basal insulin therapy is described, together with an overview of current and future basal insulin provision. Copyright © 2002 John Wiley & Sons, Ltd.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
